Wyndham H. Wilson is Head, Lymphoma Therapeutics Section and Senior Investigator of the Lymphoid Malignancy Branch, Center for Cancer Research at the National Cancer Institute.  He received his Ph.D. and M.D. at Stanford University and Stanford School of Medicine, respectively; and his post graduate training and Oncology Fellowship were completed at Stanford and the National Institutes of Health.  Wyndham is a member of several editorial boards including among others the Journal of Clinical Oncology, The Oncologist, and Blood.  He is past chair of the FDA Oncologic Drug Advisory Committee, and the NCI Institutional Review Board.  He is also a member of the Scientific Advisory Board of the Lymphoma Research Foundation, and member of the Lymphoma Steering Committee, Cooperative Groups of the Cancer Therapy Evaluation Program at NCI/NIH.  He has researched and published extensively about the diagnosis and management of Non-Hodgkin Lymphoma, and holds several patents as well as pending patents covering the diagnosis, treatment, and prediction of survival of lymphomas.  In addition to other clinical studies, Wyndham is a principal investigator of a large ongoing multinational trial in patients with various types of lymphomas.